Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccines and immunoglobulins targeting African swine fever virus and methods of making and using same

An immunoglobulin and African swine fever technology, which is applied in the fields of vaccines and immunoglobulins targeting African swine fever virus and their preparation and use, which can solve the problems of unidentified protective antigens and lack of understanding.

Pending Publication Date: 2022-07-12
IGY免疫技术和生命科学公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The challenges associated with developing a successful ASF vaccine are thought to be due to a lack of understanding of how the virus modulates the host response to infection and the lack of identification of protective antigens (Sánchez-Cordón et al., p. 44)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccines and immunoglobulins targeting African swine fever virus and methods of making and using same
  • Vaccines and immunoglobulins targeting African swine fever virus and methods of making and using same
  • Vaccines and immunoglobulins targeting African swine fever virus and methods of making and using same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0070] ASFV vaccine

[0071]The present disclosure generally relates to an ASFV vaccine comprising intact live ASFV particles in combination with naturally expressed ASF virus components, optionally diluted in sterile buffer, eg, sterile saline solution to about 10%. The ASFV vaccine can be used to actively immunize or vaccinate a non-susceptible species host for the production of ASFV-specific immunoglobulin. A non-susceptible species host can be a non-swine mammalian host, such as avian, equine, bovine, donkey, goat or rabbit.

[0072] Another aspect of the present disclosure relates generally to a method of producing an ASFV vaccine. In a preferred embodiment, the ASFV antigens are obtained from ASF-infected pigs or wild boars. In one embodiment, blood can be drawn from the ASF-infected pig or wild boar and collected in a blood collection tube with anticoagulant. The blood collection tube can be centrifuged, for example, at about 4°C at about 1,500 x g for about 15 minu...

Embodiment 1

[0126] On days 1, 14 and 28, three groups of chickens (n=3 per group) were immunized with the ASFV vaccine. Group 1 received saline (no vaccine) as a control, Group 2 received ASFV vaccine formulation 1 containing intact virions and immunosuppressive protein factors, and Group 3 received ASFV vaccine formulation 1 containing intact virions, viral components and immunosuppressive proteins Factor ASFV vaccine formulation 2. After the second and third immunization, blood samples were obtained and ASFV-specific antibody titers were assessed using recombinant ASFV major capsid protein p72-coated ELISA plates (SEQ ID NO: 2). The results of Example 1 demonstrate that the ASFV vaccine is immunogenic and immunization is achieved. Furthermore, Example 1 demonstrated that after 14 days ( Figure 4A ) and after 28 days ( Figure 4B ), the ASFV vaccine induced antibody pools with overall specificity for ASF viral components such as the ASFV major capsid protein p72 (SEQ ID NO: 2).

Embodiment 2

[0128] ASFV vaccine compositions were prepared from homogenates of ASFV-infected spleens from ASFV-infected pigs and ASFV-infected buffy coat containing PBMCs. The PBMC mixture was frozen in a dry ice ethanol bath and thawed to room temperature. The freeze-thaw procedure was repeated twice. The ASFV vaccine compositions were evaluated for active ASFV using qPCR. The results confirmed that the ASFV vaccine composition did not contain ASFV DNA. Three groups of laying hens (n=3 / group) were dosed with a control or one of two different ASFV vaccine formulations. Group 1 received saline as a control (no vaccine), group 2 received ASFV vaccine formulation 1 (prepared from SMNC), and group 3 received ASFV vaccine formulation 2 (prepared from SMNC and PBMC). The hens were actively immunized on days 1, 14 and 3 by administering ASFV vaccine (by intramuscular injection) or administering a control. Eggs were collected daily after the third immunization. Immunoglobulins were extracted...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides a method of isolating and preparing live African swine fever (ASF) virus (ASFV) and ASFV vaccines comprising intact ASF virions, viral components, and / or immunosuppressive protein factors. The ASFV vaccine may be used to immunize pigs and wild boars, or may be used to immunize species other than pigs or wild boars, such as poultry, cattle, goats, rabbits, donkeys, or horses, to produce polyclonal immunoglobulins with broad spectrum specificity for ASFV. The ASFV-specific immunoglobulins may then be extracted and purified. The ASFV-specific immunoglobulins may provide acute treatment for ASF-infected pigs or wild boars, or prophylactic treatment for pigs or wild boars at risk of ASF, for example, those may have been exposed to ASFV or ASFV infection.

Description

technical field [0001] The present disclosure generally relates to compositions for use in active and / or passive immunization for the treatment and prevention of African swine fever (ASF) virus (ASFV) infection. The present disclosure also relates to methods of isolating and preparing combinations of ASF whole virions and ASF individual viral components for use as vaccines in porcine and / or non-porcine species hosts for the production of ASFV-specific immunoglobulins. The ASFV-specific immunoglobulins disclosed herein provide broad-spectrum immunity to ASFV-infected or susceptible ASFV-infected pigs and wild boars. [0002] CROSS-REFERENCE TO RELATED APPLICATIONS [0003] This application claims the benefit of US Provisional Application 62 / 906,357, filed September 26, 2019, which is incorporated herein by reference in its entirety. [0004] sequence listing [0005] This application contains a Sequence Listing electronically filed in ASCII format and incorporated herein by ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/12A61K39/395C07K16/08C12N7/00C12N15/09
CPCA61K39/12C12N7/00C07K16/081C12N2710/12021C12N2710/12034A61K2039/552A61K2039/5252
Inventor 焕·胡·恩古叶恩
Owner IGY免疫技术和生命科学公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com